Zenocutuzumab-zbco is a bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and the human epidermal growth factor receptor 3 (HER3; ErbB3). It has enhanced antibody-dependent cellular cytotoxicity. The application was granted priority review, breakthrough designation, and orphan drug designation.
The drug is indicated for treatment of advanced non-small cell lung cancer harboring a neuregulin 1 (NRG1) gene fusion or advanced pancreatic adenocarcinoma harboring a NRG1 gene fusion after prior therapy.